DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Carmustine

Carmustine

  • Australian Public Assessment Report for Aminolevulinic Acid Hcl

    Australian Public Assessment Report for Aminolevulinic Acid Hcl

  • NOV 1 72010 1.0 Submitter

    NOV 1 72010 1.0 Submitter

  • Primary Central Nervous System Lymphoma: Consolidation Strategies

    Primary Central Nervous System Lymphoma: Consolidation Strategies

  • Wear the Battle Gear That Protects Against 52 Chemotherapy Drugs!

    Wear the Battle Gear That Protects Against 52 Chemotherapy Drugs!

  • The Effects of the Nanosphere Carrier for the Combined Carmustine-Busulfan Trastuzumab in Human Breast Cancer Tissue Culture

    The Effects of the Nanosphere Carrier for the Combined Carmustine-Busulfan Trastuzumab in Human Breast Cancer Tissue Culture

  • Phase I Clinical and Pharmacological Study of O6-Benzylguanine Followed by Carmustine in Patients with Advanced Cancer1

    Phase I Clinical and Pharmacological Study of O6-Benzylguanine Followed by Carmustine in Patients with Advanced Cancer1

  • A Guide to Safe Handling of Chemotherapy Drugs

    A Guide to Safe Handling of Chemotherapy Drugs

  • CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS

    CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS

  • Current FDA-Approved Therapies for High-Grade Malignant Gliomas

    Current FDA-Approved Therapies for High-Grade Malignant Gliomas

  • The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma

    The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma

  • Gleostine (Lomustine) Capsules

    Gleostine (Lomustine) Capsules

  • Cancer Drug Costs for a Month of Treatment at Initial Food

    Cancer Drug Costs for a Month of Treatment at Initial Food

  • NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010

    NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010

  • Extract from the Clinical Evaluation Report for Aminolevulinic Acid Hcl

    Extract from the Clinical Evaluation Report for Aminolevulinic Acid Hcl

  • Bc Cancer Chemotherapy Preparation and Stability

    Bc Cancer Chemotherapy Preparation and Stability

  • NTP Monograph on the Systematic Review of Occupational Exposure to Cancer Chemotherapy Agents and Adverse Health Outcomes

    NTP Monograph on the Systematic Review of Occupational Exposure to Cancer Chemotherapy Agents and Adverse Health Outcomes

  • Carmustine for Injection

    Carmustine for Injection

  • Local Alkylating Chemotherapy Applied Immediately After 5-ALA Guided Resection of Glioblastoma Does Not Provide Additional Benefit

    Local Alkylating Chemotherapy Applied Immediately After 5-ALA Guided Resection of Glioblastoma Does Not Provide Additional Benefit

Top View
  • New Zealand Data Sheet 1. Product Name 2. Qualitative
  • Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings
  • Threshold of Toxicological Concern (TTC) for Anticancer Compounds
  • DRUG NAME: Lomustine
  • Carmustine Replacement in Intensive Chemotherapy Preceding Reinjection of Autologous Hscs in Hodgkin and Non-Hodgkin Lymphoma: a Review
  • 208630Orig1s000
  • Local Alkylating Chemotherapy Applied Immediately After 5-ALA Guided Resection of Glioblastoma Does Not Provide Additional Benefit
  • Emetogenic Potential of Antineoplastic Agents
  • Current Treatments for Brain Tumors
  • Handling Cytostatic Drugs: Contents
  • Rapid Regression of Glioblastoma Following Carmustine Wafer Implantation: a Case Report
  • Association of High-Dose Cyclophosphamide, Cisplatin, And
  • Carmustine and Methotrexate in Combination After Whole Brain
  • Carmustine Obvius
  • A Randomized Trial of Amifostine and Carmustine-Containing Chemotherapy to Assess Lung-Protective Effects
  • Public Assessment Report
  • Pharmacist Involvement in the Management of Adverse Effects
  • Carmustine Obvius 100 Mg Powder and Solvent for Concentrate for Solution for Infusion


© 2024 Docslib.org    Feedback